M
Michael R. Kolber
Researcher at University of Alberta
Publications - 128
Citations - 1907
Michael R. Kolber is an academic researcher from University of Alberta. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 19, co-authored 115 publications receiving 1319 citations. Previous affiliations of Michael R. Kolber include University of Mississippi.
Papers
More filters
Journal Article
What are the most common conditions in primary care? Systematic review.
Caitlin R Finley,Derek S. Chan,Scott Garrison,Christina Korownyk,Michael R. Kolber,Sandra Campbell,Dean T. Eurich,Adrienne J. Lindblad,Ben Vandermeer,G. Michael Allan +9 more
TL;DR: There are differences between clinician-reported and patient-reported RFVs to primary care, as well as among countries of different economic classifications, between developed and developing countries.
Journal ArticleDOI
Treat-to-Target in Gout Management? Comment on the Article by FitzGerald et al.
Michael R. Kolber,Joey Ton +1 more
TL;DR: The scientific review team /guideline authors missed key evidence pertaining to their recommendation of "treat to target" serum uric acid (SU) levels.
Journal ArticleDOI
Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION).
Ross T. Tsuyuki,Sherilyn K.D. Houle,Theresa L. Charrois,Michael R. Kolber,Meagen Rosenthal,Richard Lewanczuk,Norm R.C. Campbell,Dale Cooney,Finlay A. McAlister +8 more
TL;DR: Pharmacist prescribing for patients with hypertension resulted in a clinically important and statistically significant reduction in BP, and policy makers should consider an expanded role for pharmacists, including prescribing, to address the burden of hypertension.
Journal ArticleDOI
Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis.
TL;DR: Intravenous iron treatment is better tolerated and more effective than oral iron treatment in improving ferritin and the combined sample size of the included studies was small and further clinical trials are required.
Journal ArticleDOI
Management of Bell palsy: clinical practice guideline
John R. de Almeida,Gordon H. Guyatt,Sachin Sud,Joanne Dorion,Michael D. Hill,Michael R. Kolber,Jane Lea,Sylvia Loong Reg,Balvinder K. Somogyi,Brian D. Westerberg,Christopher J. White,Joseph M. Chen,Neck Surgery +12 more
TL;DR: Bell palsy is an idiopathic weakness or paralysis of the face of peripheral nerve origin, with acute onset, that affects 20–30 persons per 100 000 annually and 1 in 60 individuals will be affected over the course of their lifetime.